Baseimmune unveils a new multi-pathway immunotherapy strategy, applying its computational protein design platform to develop next-generation therapies for fibrosis. Fibrosis is driven by complex and ...

Need a quote from a Motley Fool analyst? In conjunction with today's call, we have provided a presentation that will be referenced during our remarks that is posted to the Investor Relations section ...

Initiated US Phase 1/2a study of DLL3-targeting 212Pb-based Radio-DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-developed with strategic partner Orano Med; initial data ...

Data from the ongoing PIKture-01 trial is expected to be announced in March 2026; continued enrollment in breast cancer triplet combinations ...

New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and Intellectual Property Strategy Jericho, New York, March 12, 2026 (GLOBE NEWSWIRE) -- Curanex ...

Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in ...

Lipid nanoparticles, or LNPs, best known as the delivery vehicle for the COVID-19 mRNA vaccines received by billions of people, are now at the center of a much larger medical revolution.

Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiate ...